Back to Search Start Over

First Participant Vaccinated in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

Source :
M2 Pharma. June 16, 2023
Publication Year :
2023

Abstract

M2 PHARMA-June 16, 2023-First Participant Vaccinated in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs (C)2023 M2 COMMUNICATIONS - The first participant has been vaccinated in France-based biopharmaceutical company [...]

Subjects

Subjects :
Biological products industry -- Product development
Vaccination
Influenza vaccines -- Evaluation -- Product development
Viral antibodies
Influenza
Clinical trials
Antibodies
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.753212887

Tools

Authors Abstract Subjects Details